Crossmark

The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel syndrome

Crossref DOI link: https://doi.org/10.1038/s41598-024-74694-w

Published Online: 2024-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karpuzcu, Hulusi Can https://orcid.org/0000-0002-2784-2027
Turan Erdoğan, Beril https://orcid.org/0000-0003-1391-0647
Erdoğan, Çağdaş https://orcid.org/0000-0001-5903-6559
License Information

Text and Data Mining valid from 2024-10-21

Version of Record valid from 2024-10-21
More Information

Article History

Received: 21 March 2024

Accepted: 27 September 2024

First Online: 21 October 2024

Declarations

:

: The authors declare no competing interests.

: This study complied with the ethical guidelines of the 1975 Helsinki Declaration that was then modified in 2008. The study protocol was approved by Ankara Etlik City Hospital ethics committee (AEŞH-EK1-2023-494).

Document is current

Any future updates will be listed below